Dentsply Sirona Inc Stock Price, News & Analysis

Dentsply Sirona (NASDAQ:XRAY), the world's largest diversified dental manufacturer, has appointed Aldo M. Denti as Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025.

Denti brings over 25 years of experience in Medical Device and Consumer Health sectors, most recently serving as Company Group Chairman, Global Orthopedics at Johnson & Johnson Medtech. The appointment aims to enhance customer focus by aligning Global Business Units and Commercial Organizations, streamlining operations and delivery processes.

CEO Daniel Scavilla highlighted that Denti will lead global sales strategy and execution to drive growth, profitability, and customer satisfaction across all regions. The new CCO role is designed to strengthen collaboration across business units and unlock synergies.

Dentsply Sirona (Nasdaq: XRAY) has announced its decision to retain Wellspect Healthcare as a subsidiary following a comprehensive strategic review initiated in February 2025. The company determined that keeping Wellspect within its portfolio would create more value for stockholders than other alternatives, including potential sale options.

Wellspect, a leading provider of bladder and bowel care products with a 40-year history, has demonstrated strong performance with mid-single digit growth in 2024. The business operates in the continence care market, which has an estimated $2 billion addressable market. CEO Dan Scavilla emphasized Wellspect's position as a category leader with strong cash flow generation and significant market potential.

Dentsply Sirona (NASDAQ:XRAY), a dental products company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 2:35 PM ET and the Baird Global Healthcare Conference on September 9 at 1:25 PM ET.

Investors can access live audio webcasts and replays of both presentations through the Investors section of Dentsply Sirona's website.

Dentsply Sirona (NASDAQ:XRAY) reported challenging Q2 2025 results with net sales declining to $936 million, down 4.9% (6.7% in constant currency). The company posted a GAAP net loss of ($0.22) per share, impacted by a significant $214 million non-cash impairment charge. Despite revenue challenges, adjusted earnings per share increased to $0.52 from $0.49 year-over-year.

Notable developments include a $550 million debt offering and key leadership changes, with Dan Scavilla appointed as CEO and Matt Garth as CFO. The company maintained its FY25 outlook, projecting net sales of $3.60-3.70 billion and adjusted EPS of $1.80-2.00. Margin performance showed improvement with adjusted EBITDA margin reaching 21.1%, up from 17.5% in Q2 2024.

Dentsply Sirona (NASDAQ: XRAY) has appointed Daniel Scavilla as its new President and CEO, effective August 1, 2025, succeeding Simon Campion. Scavilla, a current board member with over 30 years of experience in medical technology, previously served as CEO of Globus Medical and held leadership roles at Johnson & Johnson.

The company also released preliminary Q2 2025 results, expecting net sales of approximately $935 million and adjusted EPS between $0.50-$0.52. Dentsply Sirona has reaffirmed its full-year 2025 outlook previously provided in May 2025, with final Q2 results to be reported on August 7, 2025.

Dentsply Sirona (Nasdaq: XRAY) has announced it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results. The event is scheduled for Thursday, August 7, 2025, at 8:30 am ET.

Prior to the call, the company will release its financial results and provide a presentation with summary financial information on its investor relations website. Interested participants can register for the call through the provided link, and a webcast replay will be available after the event.

Dentsply Sirona (XRAY) has priced an offering of $550 million in Junior Subordinated Notes due 2055 with an initial fixed interest rate of 8.375% until September 12, 2030. After the First Reset Date, the interest rate will be based on the five-year U.S. Treasury rate plus a 4.379% spread, with a minimum rate of 8.375%. The notes will pay interest semi-annually starting September 12, 2025. The company expects net proceeds of approximately $544.5 million after underwriting discounts, which will be used for general corporate purposes, including repaying a $435 million term loan and other short-term debt. Goldman Sachs is serving as the sole book-running manager, with PNC Capital Markets, Commerz Markets, Truist Securities, and MUFG Securities Americas as co-managers.

Dentsply Sirona (NASDAQ: XRAY) has appointed Matthew E. Garth as Executive Vice President and Chief Financial Officer, effective May 30, 2025. Garth brings nearly 30 years of financial management experience, most recently serving as CFO & Chief Administrative Officer at The Scotts Miracle-Gro Company. His previous roles include financial leadership positions at Minerals Technology Inc. and Alcoa Corporation.

CEO Simon Campion highlighted Garth's expertise in organizational transformation and capital markets engagement, emphasizing his potential role in advancing Dentsply Sirona's strategic agenda for sustainable growth and shareholder value creation. Garth expressed enthusiasm about joining the company and contributing to its financial, operational, and strategic objectives.

Dentsply Sirona (NASDAQ: XRAY) has announced a quarterly cash dividend declaration. The Board of Directors has approved a dividend payment of $0.16 per share of common stock, which translates to an indicated annual rate of $0.64 per share. Shareholders who are holders of record as of June 27, 2025, will receive the dividend payment on July 11, 2025.